BioMarin Announces Initiation Of Clinical Assessment Program For Morquio A Syndrome BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced the initiation of the Morquio Clinical Assessment Program (MorCAP) for patients with the lysosomal storage disease Mucopolysaccharidosis Type IVA (MPS IVA), or Morquio A Syndrome. MorCAP is designed to augment available data on the disease by measuring endurance and respiratory function and other parameters in affected patients.
Source: www.medicalnewstoday.comRomark Announces Presentation Of New Data For Nitazoxanide In Chronic Hepatitis C At AASLD 2008 Romark Laboratories, a privately held biopharmaceutical company, announced that data from studies of nitazoxanide in chronic hepatitis C virus (HCV) infection are being communicated in three presentations made at the 59th Annual Meeting of the American Association for
Source: www.medicalnewstoday.com
# posted by Network @ 6:00 PM
